Dr. Jae Hong Park, MD

Dr. Park practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Park's NPI, 1669593000, was assigned on April 3, 2007. Dr. Park graduated from The Johns Hopkins University School of Medicine in 2005. Dr. Park's New York license number on file is 726324.

Dr. Park's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Park's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Park to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Park practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Park's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Park is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Park's licenses on file in 8 states: New York, Florida, Connecticut, New Hampshire, North Carolina, Maine, Oklahoma and Massachusetts.

Dmand AI lists anemia, breast cancer, chronic anemia, chronic leukemia, lymphoma, multiple myeloma, neutropenia and prostate cancer among the conditions Dr. Park treats.

CMS data shows 668 Medicare services from Dr. Park across 7 procedure codes in 2024, for 256 Medicare patients. Medicare paid $61,043 for them.

CMS counts 256 Medicare patients who saw Dr. Park in 2024. The largest group is 65 to 74, with 113 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Park's median patient age at 73, with 47% women.

In 2024, Dr. Park wrote 47 Medicare Part D claims for 22 patients. 66% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $123 in total drug cost. In 2021, CMS named 65 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Park for performance year 2024, reported as part of a group. Dr. Park accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Park as offering telehealth.

Dmand AI links 122 papers to Dr. Park, published from 2011 to 2025. 2025 was the busiest year, with 12. The most frequent topics are Immunotherapy, Adoptive, Receptors, Chimeric Antigen and Antigens, CD19. Dr. Park has published most often in Blood. Dr. Park's most frequent co-authors are Miguel A. Perales, MD, Gunjan Lalitchandra Shah, MD and Martin S. Tallman, MD.

Dmand AI links Dr. Park to 16 clinical trials, 8 of them phase 1 studies. 11 are still active or recruiting. Conditions studied include Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid and Leukemia. Memorial Sloan Kettering Cancer Center sponsors the most, 14.

CMS Open Payments shows 279 general payments to Dr. Park from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 69% of the total. Amgen Inc. paid the most, $107,623. It also lists 3 research payments totaling $5,562 from 2019 to 2024.

Dr. Park graduated from The Johns Hopkins University School of Medicine in 2005.

Dr. Park is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.